Alzchem Beats Q2 Sales Forecasts, Reaffirms Full-Year Guidance

Alzchem Group AG (ACT1) reported second-quarter sales that surpassed consensus estimates, underpinned by robust volume and price growth in its Specialty Chemicals segment. The German chemical company reaffirmed its full-year guidance for 2026, signaling confidence in its operational performance and strategic growth projects.

Quarterly Performance in Detail

The company announced second-quarter sales of €155.3 million, an increase of 8.7% year-over-year and 4.6% ahead of the company's consensus forecast of €148.5 million. The sales growth was composed of a 5.1% increase in volume and a 4.2% rise in prices, partially offset by a 0.6% negative foreign exchange effect.

Key profitability metrics for the quarter included:

• EBITDA: €32.2 million, in line with market expectations.
• Operating Profit: Rose 9% to €24.7 million compared to the prior-year quarter.
• Earnings Per Share (EPS): Increased by 6% to €1.66.

Specialty Chemicals Drive Growth

Ad

The primary driver of the strong quarterly results was the Specialty Chemicals division, which saw price increases of 6.5% and volume growth of 2.8%. Alzchem attributed this performance to continued high demand for its creatine and nitroguanidine products. The company noted that its overall profitability improved due to a higher proportion of these high-margin specialty products in its sales mix.

In contrast, the Basic and Intermediates segment experienced a 2.1% price decline, although this was more than offset by strong volume growth of 11.5%.

Outlook and Strategic Investments

Alzchem maintained its full-year 2026 forecast, projecting sales growth of approximately 7% to around €600 million and EBITDA growth of about 8% to €126 million. The company's capacity expansion projects for nitroguanidine and creatine are proceeding as planned, with the company selecting Bushy Park, South Carolina, as the site for its new US nitroguanidine production facility.

Despite the positive earnings, free cash flow was negative at -€31.6 million, compared to -€5.7 million in the same quarter of 2025. The company cited higher investments and working capital needs for the outflow. However, net debt improved, falling to €22.3 million from €30.6 million at the end of fiscal 2025.